Vaccine

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth…

3 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product…

3 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd.…

3 months ago

AI in Oncology For Analytical Solutions Market Size & Share to Surpass $8.86 Billion by 2035, Growing at a CAGR 21% | Vantage Market Research

Global AI in Oncology For Analytical Solutions Market to Transform Cancer Care Accelerating Early Detection, Precision Treatment, and Patient Outcomes.…

3 months ago

Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices

PHOENIX, Sept. 22, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment…

3 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key…

3 months ago

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured…

3 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025…

3 months ago

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage…

3 months ago